CONTEXT: Depression strongly predicts nonadherence to human immunodeficiency virus (HIV) antiretroviral therapy, and adherence is essential to maintaining viral suppression. This suggests that pharmacologic treatment of depression may improve virologic outcomes. However, previous longitudinal observational analyses have inadequately adjusted for time-varying confounding by depression severity, which could yield biased estimates of treatment effect. Application of marginal structural modeling to longitudinal observation data can, under certain assumptions, approximate the findings of a randomized controlled trial. OBJECTIVE: To determine whether antidepressant medication treatment increases the probability of HIV viral suppression. DESIGN: Community-based prospective cohort study with assessments conducted every 3 months. SETTING: Community-based research field site in San Francisco, California. PARTICIPANTS: One hundred fifty-eight homeless and marginally housed persons with HIV who met baseline immunologic (CD4+ T-lymphocyte count, <350/μL) and psychiatric (Beck Depression Inventory II score, >13) inclusion criteria, observed from April 2002 through August 2007. MAIN OUTCOME MEASURES: Probability of achieving viral suppression to less than 50 copies/mL. Secondary outcomes of interest were probability of being on an antiretroviral therapy regimen, 7-day self-reported percentage adherence to antiretroviral therapy, and probability of reporting complete (100%) adherence. RESULTS: Marginal structural models estimated a 2.03 greater odds of achieving viral suppression (95% confidence interval [CI], 1.15-3.58; P = .02) resulting from antidepressant medication treatment. In addition, antidepressant medication use increased the probability of antiretroviral uptake (weighted odds ratio, 3.87; 95% CI, 1.98-7.58; P < .001). Self-reported adherence to antiretroviral therapy increased by 25 percentage points (95% CI, 14-36; P < .001), and the odds of reporting complete adherence nearly doubled (weighted odds ratio, 1.94; 95% CI, 1.20-3.13; P = .006). CONCLUSIONS: Antidepressant medication treatment increases viral suppression among persons with HIV. This effect is likely attributable to improved adherence to a continuum of HIV care, including increased uptake and adherence to antiretroviral therapy.
CONTEXT: Depression strongly predicts nonadherence to human immunodeficiency virus (HIV) antiretroviral therapy, and adherence is essential to maintaining viral suppression. This suggests that pharmacologic treatment of depression may improve virologic outcomes. However, previous longitudinal observational analyses have inadequately adjusted for time-varying confounding by depression severity, which could yield biased estimates of treatment effect. Application of marginal structural modeling to longitudinal observation data can, under certain assumptions, approximate the findings of a randomized controlled trial. OBJECTIVE: To determine whether antidepressant medication treatment increases the probability of HIV viral suppression. DESIGN: Community-based prospective cohort study with assessments conducted every 3 months. SETTING: Community-based research field site in San Francisco, California. PARTICIPANTS: One hundred fifty-eight homeless and marginally housed persons with HIV who met baseline immunologic (CD4+ T-lymphocyte count, <350/μL) and psychiatric (Beck Depression Inventory II score, >13) inclusion criteria, observed from April 2002 through August 2007. MAIN OUTCOME MEASURES: Probability of achieving viral suppression to less than 50 copies/mL. Secondary outcomes of interest were probability of being on an antiretroviral therapy regimen, 7-day self-reported percentage adherence to antiretroviral therapy, and probability of reporting complete (100%) adherence. RESULTS: Marginal structural models estimated a 2.03 greater odds of achieving viral suppression (95% confidence interval [CI], 1.15-3.58; P = .02) resulting from antidepressant medication treatment. In addition, antidepressant medication use increased the probability of antiretroviral uptake (weighted odds ratio, 3.87; 95% CI, 1.98-7.58; P < .001). Self-reported adherence to antiretroviral therapy increased by 25 percentage points (95% CI, 14-36; P < .001), and the odds of reporting complete adherence nearly doubled (weighted odds ratio, 1.94; 95% CI, 1.20-3.13; P = .006). CONCLUSIONS: Antidepressant medication treatment increases viral suppression among persons with HIV. This effect is likely attributable to improved adherence to a continuum of HIV care, including increased uptake and adherence to antiretroviral therapy.
Authors: Marjorie J Robertson; Richard A Clark; Edwin D Charlebois; Jacqueline Tulsky; Heather L Long; David R Bangsberg; Andrew R Moss Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Andrew R Moss; Judith A Hahn; Sharon Perry; Edwin D Charlebois; David Guzman; Richard A Clark; David R Bangsberg Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1976-12 Impact factor: 7.640
Authors: Alexander C Tsai; Dan H Karasic; Gwendolyn P Hammer; Edwin D Charlebois; Kathy Ragland; Andrew R Moss; James L Sorensen; James W Dilley; David R Bangsberg Journal: Am J Public Health Date: 2012-06-21 Impact factor: 9.308
Authors: Keith A Hermanstyne; Glenn-Milo Santos; Eric Vittinghoff; Deirdre Santos; Grant Colfax; Phillip Coffin Journal: Drug Alcohol Depend Date: 2014-08-05 Impact factor: 4.492
Authors: Alexander C Tsai; Sheri D Weiser; Samantha E Dilworth; Martha Shumway; Elise D Riley Journal: Am J Epidemiol Date: 2015-03-31 Impact factor: 4.897
Authors: Nadine E Chen; Jaimie P Meyer; Ann K Avery; Jeffrey Draine; Timothy P Flanigan; Thomas Lincoln; Anne C Spaulding; Sandra A Springer; Frederick L Altice Journal: AIDS Behav Date: 2013-10
Authors: Michael B Blank; Seth S Himelhoch; Alexandra B Balaji; David S Metzger; Lisa B Dixon; Charles E Rose; Emeka Oraka; Annet Davis-Vogel; William W Thompson; James D Heffelfinger Journal: Am J Public Health Date: 2014-02-13 Impact factor: 9.308